ND 420

Drug Profile

ND 420

Alternative Names: ND-420

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Nang Kuang Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Oesophageal cancer

Most Recent Events

  • 28 Mar 2017 Nang Kuang Pharmaceutical terminates phase II trial in Oesophageal cancer (Combination therapy, Neoadjuvant therapy) in Taiwan (NCT02017600)
  • 02 Mar 2016 No development reported - Phase-II for Oesophageal cancer (Combination therapy, Neoadjuvant therapy) in Taiwan (unspecified route)
  • 07 Feb 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top